查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018944

癌症生物疗法市场：2026-2032年全球市场预测（依治疗方法、给药途径、应用、最终用户和分销管道划分）

Cancer Biological Therapy Market by Therapy Type, Administration Route, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，癌症生物疗法市场价值将达到 812.5 亿美元，到 2026 年将成长至 911.7 亿美元，到 2032 年将达到 1,785 亿美元，年复合成长率为 11.89%。

主要市场统计数据
基准年 2025 812.5亿美元
预计年份：2026年 911.7亿美元
预测年份 2032 1785亿美元
复合年增长率 (%) 11.89%

本报告将科学突破、营运挑战和相关人员的优先事项纳入策略规划，整体情况了现代癌症生物疗法。

癌症生物疗法正处于转型期，其特征是分子科学、转化平台和以患者为中心的治疗路径的融合。免疫肿瘤学、基因修饰细胞疗法和标靶生技药品的进步正在重塑临床实践和产业运营，促使相关人员重新评估研发、生产和商业化等各个环节的策略重点。本文概述了当前的产业格局，重点在于推动策略决策的科学转折点、供应链现状以及相关人员的期望。

找出关键的科学、製造和支付方主导的变革，这些变革将从根本上改变新型生物製药的开发、製造和报销方式。

癌症生物治疗领域正经历一系列变革性的转变，这些变革涵盖了从实验室到临床，贯穿整个价值链。高精度分子谱分析和新型抗原发现工具正在拓展标靶领域，并协助疫苗、基因修饰细胞产品和溶瘤平台的精准设计。载体设计、基因编辑精准度与免疫调节结构的改进，进一步推动了这项科学发展势头，共同提升了新型生物製药的治疗指数。随着转化路径的日趋成熟，临床试验设计变得更加灵活，并以生物标记主导，讯号检测速度加快，试验的启动或终止决策也能够更早做出。

本研究分析了 2025 年贸易政策调整将如何影响生物製药的供应链、製造地的决策以及整个生态系统对策略采购的应对措施。

美国于2025年实施的新关税和贸易措施进一步加剧了生物製药全球供应链的复杂性。随着製造商重新评估供应商所在地和紧急储备，原料采购、关键试剂的供应以及专用设备的进口再次受到严格审查。为此，许多相关人员正在加快供应商多元化和近岸外包策略，以维持供应的连续性并降低关税变化带来的风险。

这个过程阐明了治疗方法、适应症、给药途径、最终用户和分销等主题中微妙的策略意义，从而明确了开发和商业化选择。

基于细分市场的观点揭示了生物製药整体情况中临床、营运和商业性差异最为显着的领域。根据治疗方法类型，该市场涵盖多种疗法，例如癌症疫苗、CAR-T细胞疗法、细胞激素疗法、基因疗法、单株抗体和溶瘤病毒疗法，单株抗体可进一步细分为嵌合体、人源型、人源化型和鼠源型。每种疗法都有其独特的研发考量和临床应用领域。这些疗法的差异会影响监管的复杂性、製造地以及证明其广泛应用所需的临床证据。

该工具比较了美洲、欧洲、中东和非洲以及亚太地区的创新生态系统、监管管道和准入促进因素，以帮助企业做出市场进入决策。

区域趋势持续影响创新方向、产品生产方式，以及最重要的病患获取途径。在美洲，健全的临床试验体系、成熟的生物技术投资者基础和完善的报销机制，共同创造了有利于快速临床应用和与支付方谈判的环境。然而，支付方的分散性以及处方集的区域处方集，要求申办方制定循证策略，以应对不同的入组标准和卫生经济预期。

本分析检视了推动生物肿瘤学领域能力建构、生产扩张和产品组合差异化的企业策略和伙伴关係趋势。

生物治疗领域的企业发展趋势融合了专业化、协作和策略整合。大型製药企业正日益与灵活的生物技术公司合作，以获取前沿平台，同时发挥自身在扩大研发规模和全球商业化方面的优势。合约研发生产机构（CDMO）在推动每种治疗方法的规模化生产中发挥核心作用，许多CDMO正在扩展其能力，以支持细胞和基因治疗工作流程、分析测试以及低温运输物流。

为研发和生产企业提供切实可行的策略步骤，以加强其产品线、扩大生产规模，并在快速发展的肿瘤生态系统中获得报销途径。

产业领导者应推动一系列切实可行的倡议，以提升开发平臺、营运准备度和市场进入成果。首先，在研发早期阶段优先考虑平台稳健性和流程标准化，以便在后期阶段促进规模化生产、监管申报和技术转移。投资模组化製造和检验的供应链将缩短产品交付给患者的时间，并使其能够更灵活地应对需求波动。其次，将卫生经济学和结果研究纳入临床项目，以确保从早期申报到产品上市，在与支付方的讨论中充分体现产品的持久性和真实世界获益。

本报告概述了综合的一手和二手研究途径、检验过程和局限性，以确保本报告的策略可信度和背景考量。

本执行摘要的研究基础是将对行业专家、临床研究人员、生产专家和支付方顾问的定性访谈与对同行评审文献、监管指导文件、临床试验註册资讯和企业资讯披露的系统性二次文献回顾相结合。主要资讯透过结构化访谈收集，旨在检验营运假设、澄清监管解释并揭示生产和商业化策略的实际案例。二级资讯来源的选择是基于相关性和时效性，以确保与当前的科学和政策发展保持一致。

这概括了整合科学潜力、营运准备和相关人员合作的策略重点，以加速扩大患者获取途径和专案永续性。

总之，癌症生物疗法正处于一个转折点，科学预期与实际操作能力日益趋于一致，但在供应链韧性、监管协调和支付方接受度方面仍面临挑战。本执行摘要整合了近期技术进步、生产趋势和政策发展，旨在为致力于将科学突破转化为可及治疗方法的利益相关人员明确优先事项。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 癌症生物疗法市场（依治疗方法划分）

  • 癌症疫苗
  • CAR-T细胞疗法
  • 细胞激素疗法
  • 基因治疗
  • 单株抗体
    • 嵌合体
    • 人类
    • 人性化
    • 小鼠来源
  • 溶瘤病毒疗法

第九章：按给药途径分類的癌症生物疗法市场

  • 肌肉内部
  • 静脉
  • 口服
  • 皮下

第十章 癌症生物疗法市场：依应用领域划分

  • 乳癌
  • 结肠癌
  • 骨髓恶性肿瘤
  • 恶性黑色素瘤
  • 非小细胞肺癌
  • 摄护腺癌

第十一章 癌症生物疗法市场：以最终用户划分

  • 门诊部
  • 家庭医疗保健
  • 医院
  • 研究机构
  • 专科诊所

第十二章 癌症生物疗法市场：依分销管道划分

  • 直销
  • 医院药房
  • 网路药房
  • 零售药房

第十三章 癌症生物疗法市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：癌症生物疗法市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 癌症生物疗法市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国癌症生物疗法市场

第十七章：中国癌症生物疗法市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Incyte Corp
  • Johnson & Johnson
  • Johnson & Johnson Services, Inc,
  • Merck & Co. Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc
  • Sanofi SA
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-B72AD18D0F9C

The Cancer Biological Therapy Market was valued at USD 81.25 billion in 2025 and is projected to grow to USD 91.17 billion in 2026, with a CAGR of 11.89%, reaching USD 178.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 81.25 billion
Estimated Year [2026] USD 91.17 billion
Forecast Year [2032] USD 178.50 billion
CAGR (%) 11.89%

Framing the contemporary cancer biological therapy landscape by synthesizing scientific breakthroughs, operational challenges, and stakeholder priorities for strategic planning

Cancer biological therapy has entered a transitional phase defined by convergence between molecular science, translational platforms, and patient-centered care pathways. Advances in immuno-oncology, engineered cell therapies, and targeted biologics have reshaped both clinical practice and industrial operations, prompting stakeholders to re-evaluate strategic priorities across research, development, manufacturing, and commercialization. This introduction frames the contemporary landscape by highlighting the scientific inflection points, supply chain realities, and stakeholder expectations that together drive strategic decision-making.

Over recent years, developers and care providers have moved from proof-of-concept demonstrations toward scalable clinical programs and integrated care models. As a result, clinical teams and executives must reconcile long-term scientific opportunity with near-term operational constraints. In this context, research institutions, contract development organizations, and commercial manufacturers are collaborating more closely to de-risk late-stage development and enable smoother transitions to wider patient access. Consequently, leaders are prioritizing platform robustness, manufacturing agility, and evidence generation that supports regulatory and payer engagement.

The remainder of this executive summary is structured to present the transformative shifts shaping therapeutic innovation, the trade policy headwinds influencing supply chains, segmentation-informed strategic insights, regional dynamics, leading corporate behaviors, and pragmatic recommendations for industry leaders. Together, these elements provide a concise synthesis that supports informed strategy-setting and resource prioritization in a rapidly evolving field.

Identifying the pivotal scientific, manufacturing, and payer-driven transformations fundamentally altering how novel cancer biologics are developed, produced, and reimbursed

The field of cancer biological therapy is being reshaped by a set of transformative shifts that extend from bench to bedside and across value chains. High-fidelity molecular profiling and new antigen discovery tools have expanded the target space, enabling more precise design of vaccines, engineered cell products, and oncolytic platforms. This scientific momentum is complemented by enhancements in vector design, gene editing accuracy, and immunomodulatory constructs, which collectively increase the therapeutic index of novel biologics. As translational pathways mature, trial designs have become more adaptive and biomarker-driven, accelerating signal detection and enabling earlier go/no-go decisions.

Concurrently, manufacturing innovations are improving the feasibility of complex modalities. Modular and closed-system manufacturing approaches reduce contamination risk and support decentralized production models, while single-use technologies and process intensification techniques enhance throughput for cell- and gene-based therapeutics. These operational gains are fostering new commercialization approaches, including hub-and-spoke and hybrid fulfillment networks that bring specialized therapies closer to patients without compromising quality.

From a market perspective, payer engagement and health technology assessment processes are evolving to accommodate durable responses and curative potential. Real-world evidence generation and outcomes-based contracting are becoming central to reimbursement discussions, prompting sponsors to integrate long-term follow-up and health economics into early development plans. Taken together, these shifts are redefining how scientific opportunity is translated into sustainable patient access and lasting commercial value.

Analyzing how 2025 trade policy adjustments influence biological therapy supply chains, manufacturing placement decisions, and strategic sourcing responses across the ecosystem

The introduction of new tariffs and trade measures in the United States in 2025 has introduced additional complexity into global supply chains for biological therapeutics. Raw material sourcing, critical reagent availability, and the importation of specialized equipment face renewed scrutiny as manufacturers reassess vendor footprints and contingency inventories. In response, many stakeholders are accelerating supplier diversification and nearshoring strategies to preserve continuity of supply and to mitigate exposure to tariff volatility.

Beyond direct input costs, tariffs have influenced logistical planning and capital allocation. Sponsors and contract manufacturers are reevaluating the placement of high-value manufacturing assets and the trade-offs between centralized scale and regionalized resilience. As a consequence, firms are increasing investment in local regulatory expertise and in-country quality systems to streamline cross-border transfers and reduce the administrative friction associated with customs and compliance.

Strategic responses also include enhanced collaboration across the value chain. Long-term supplier agreements, co-investment in regional production capacity, and vertical integration of critical upstream capabilities have become more pragmatic ways to stabilize costs and timelines. At the policy level, industry engagement with trade authorities and participation in multilateral forums are being deployed to clarify tariff schedules and to advocate for exemptions that reflect the public health nature of many biological therapies. These combined measures aim to ensure that patient access is preserved while commercial and operational risks are actively managed.

Revealing nuanced strategic implications across modality, indication, administration route, end user, and distribution axes to sharpen development and commercialization choices

A segmentation-informed perspective clarifies where clinical, operational, and commercial differentiation is most pronounced across the biological therapy landscape. Based on therapy type, the market encompasses modalities including cancer vaccines, CAR T-cell therapy, cytokine therapy, gene therapy, monoclonal antibodies, and oncolytic viral therapy, with monoclonal antibodies further divided into chimeric, human, humanized, and murine formats, each presenting distinct development considerations and clinical niches. These modality distinctions influence regulatory complexity, manufacturing footprints, and the clinical evidence required to support broad adoption.

Based on application, biologics address a spectrum of tumor types, notably breast cancer, colorectal cancer, hematologic malignancies, melanoma, non-small cell lung cancer, and prostate cancer. Each indication has unique patient pathways and standard-of-care backdrops that shape trial design and commercial access strategies. Based on administration route, products are delivered intramuscularly, intravenously, orally, or subcutaneously, which affects patient experience, site-of-care selection, and distribution logistics. These choices, in turn, shape commercialization playbooks and patient adherence considerations.

Based on end user, the clinical ecosystem spans ambulatory care centers, home healthcare, hospitals, research laboratories, and specialty clinics, and each setting imposes different infrastructure and training requirements. Finally, based on distribution channel, therapies move through direct sales, hospital pharmacies, online pharmacies, and retail pharmacies, which dictates go-to-market models and patient support infrastructure. Understanding how these segmentation axes intersect allows leaders to prioritize investments in clinical operations, supply chain design, and stakeholder engagement that are most relevant to their specific modality and therapeutic area.

Comparing regional innovation ecosystems, regulatory pathways, and access drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform market entry decisions

Regional dynamics continue to shape where innovation is pursued, how products are manufactured, and the patient access pathways that matter most. In the Americas, robust clinical trial ecosystems, a mature biotech investor base, and established reimbursement frameworks create an environment that supports rapid clinical translation and payer negotiation. However, fragmentation across payers and variability in regional formularies require sponsors to design evidence strategies that address diverse coverage criteria and health economics expectations.

In Europe, the Middle East & Africa region, regulatory harmonization and centralized pathways coexist with country-level access heterogeneity. This mix necessitates tailored regulatory strategies and differentiated value dossiers that reflect local clinical practice and health system priorities. Emerging markets within the region present growing patient populations and unique unmet medical needs, but they also demand pragmatic pricing and distribution approaches that account for infrastructure constraints.

Across Asia-Pacific, governments are increasingly prioritizing domestic biopharmaceutical capability, investing in manufacturing capacity and regulatory modernization. These shifts are encouraging partnerships between multinational developers and regional manufacturers, and they are enabling accelerated approvals for therapies that address high-burden indications. Collectively, regional forces underscore the importance of adaptive market entry strategies that balance global platform advantages with nuanced local execution and stakeholder engagement.

Distilling corporate strategies and partnership dynamics that drive capability building, manufacturing expansion, and portfolio differentiation in biological oncology

Corporate behavior in the biological therapy space reflects a mix of specialization, collaboration, and strategic consolidation. Large pharmaceutical companies are increasingly partnering with nimble biotechnology firms to access cutting-edge platforms while leveraging their own strengths in development scale-up and global commercialization. Contract development and manufacturing organizations play a central role in enabling modality-specific scale, and many have expanded capabilities to support cell and gene therapy workflows, analytical testing, and cold-chain logistics.

At the same time, mid-sized and emerging companies are differentiating through niche scientific platforms, targeted indications, and novel delivery formats. These firms often pursue strategic partnerships with academic centers and clinical networks to access patient populations and translational expertise. Strategic alliances and licensing agreements remain prolific as companies seek to accelerate clinical timelines without shouldering all development risk internally. Mergers and acquisitions are typically motivated by the desire to acquire platform capabilities, expand manufacturing capacity, or secure late-stage assets that complement existing portfolios.

Investor interest remains focused on proven translational pathways and on companies that demonstrate operational readiness to scale. As a result, firms that can present integrated plans for evidence generation, manufacturing, and commercialization tend to command strategic attention from partners and acquirers alike. Overall, corporate strategies emphasize operational resilience, flexible manufacturing models, and the capacity to generate robust clinical and economic evidence.

Actionable strategic moves for developers and manufacturers to fortify pipelines, scale manufacturing, and secure reimbursement pathways in a rapidly evolving oncology ecosystem

Industry leaders should pursue a set of pragmatic actions to strengthen development pipelines, operational readiness, and market access outcomes. First, prioritize platform robustness and process standardization early in development to ease later-stage scale-up, regulatory submissions, and technology transfers. Investing in modular manufacturing and validated supply chains will reduce time to patient and allow more flexible responses to demand fluctuations. Second, embed health economics and outcomes research into clinical programs so that evidence for durability and real-world benefit informs payer discussions from initial dossier development through launch.

Third, accelerate partnerships across academia, clinical networks, and contract manufacturing organizations to share risk and to access specialized capabilities rapidly. Strategic alliances should be structured to include clear milestone-based governance and data-sharing agreements that protect intellectual property while enabling translational progress. Fourth, develop patient-centric service models that simplify administration and follow-up, such as bridging hub services, decentralized trial elements, and remote monitoring, which can improve adherence and support long-term outcome collection. Finally, engage proactively with regulators and trade authorities to anticipate policy changes, advocate for clarity on cross-border flows, and seek pathways that preserve timely patient access while maintaining safety and quality standards.

Explaining the integrated primary and secondary research approach, validation processes, and limitations that ensure the report's strategic reliability and context awareness

The research underpinning this executive summary integrates primary qualitative engagement with industry experts, clinical investigators, manufacturing specialists, and payer advisors together with systematic secondary review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures. Primary inputs were obtained through structured interviews designed to validate operational assumptions, clarify regulatory interpretation, and surface practical case examples of manufacturing and commercialization strategies. Secondary sources were selected for relevance and recency to ensure alignment with current scientific and policy developments.

Data triangulation was applied to reconcile differing perspectives and to identify consistent themes across stakeholders. Where possible, clinical outcomes and regulatory precedents were corroborated against publicly available trial records and approval documentation. Limitations of this approach include potential selection bias inherent in expert interviews and the constantly shifting nature of policy and clinical evidence, which means that readers should treat the findings as a strategic synthesis rather than an immutable prediction. To mitigate these constraints, the research emphasizes transparent assumptions and recommends periodic updates to reflect new approvals, guideline changes, and material policy shifts.

Summarizing the strategic takeaways that integrate scientific potential, operational readiness, and stakeholder alignment to accelerate patient access and program sustainability

In conclusion, cancer biological therapy stands at an inflection point where scientific promise is increasingly matched by operational capability, yet persistent challenges remain in supply chain resilience, regulatory alignment, and payer acceptance. By synthesizing recent technological advances, manufacturing trends, and policy developments, this executive summary identifies clear priorities for stakeholders seeking to translate scientific breakthroughs into accessible therapies.

Leaders that align platform development with scalable manufacturing, invest in evidence generation that addresses payer needs, and adopt flexible market entry strategies across regions will be better positioned to convert clinical success into durable patient access. Continued collaboration across industry, regulators, and clinical communities will be essential to navigate tariff-driven supply chain adjustments and to sustain momentum toward improved outcomes for patients with cancer. The combined focus on operational readiness, strategic partnerships, and patient-centered commercialization will determine which programs realize their full clinical and societal potential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Biological Therapy Market, by Therapy Type

  • 8.1. Cancer Vaccines
  • 8.2. CAR T-Cell Therapy
  • 8.3. Cytokine Therapy
  • 8.4. Gene Therapy
  • 8.5. Monoclonal Antibodies
    • 8.5.1. Chimeric
    • 8.5.2. Human
    • 8.5.3. Humanized
    • 8.5.4. Murine
  • 8.6. Oncolytic Viral Therapy

9. Cancer Biological Therapy Market, by Administration Route

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Cancer Biological Therapy Market, by Application

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Hematologic Malignancies
  • 10.4. Melanoma
  • 10.5. Non-Small Cell Lung Cancer
  • 10.6. Prostate Cancer

11. Cancer Biological Therapy Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Research Laboratories
  • 11.5. Specialty Clinics

12. Cancer Biological Therapy Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Cancer Biological Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Biological Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Biological Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cancer Biological Therapy Market

17. China Cancer Biological Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc
  • 18.6. Amgen Inc.
  • 18.7. Astellas Pharma Inc.
  • 18.8. AstraZeneca plc
  • 18.9. Bausch Health Companies Inc.
  • 18.10. Bayer AG
  • 18.11. Biogen Inc.
  • 18.12. bluebird bio, Inc.
  • 18.13. Bristol-Myers Squibb Company
  • 18.14. Eisai Co., Ltd.
  • 18.15. Eli Lilly and Company
  • 18.16. F. Hoffmann-La Roche Ltd
  • 18.17. Gilead Sciences, Inc
  • 18.18. GlaxoSmithKline PLC
  • 18.19. Hikma Pharmaceuticals PLC
  • 18.20. Incyte Corp
  • 18.21. Johnson & Johnson
  • 18.22. Johnson & Johnson Services, Inc,
  • 18.23. Merck & Co. Inc
  • 18.24. Novartis AG
  • 18.25. Otsuka Pharmaceutical Co., Ltd
  • 18.26. Pfizer Inc
  • 18.27. Sanofi SA
  • 18.28. Spectrum Pharmaceuticals, Inc.
  • 18.29. Takeda Pharmaceutical Company Limited
  • 18.30. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)